Tagworks publishes convincing results of cancer therapy in mice in Nature Communications

In mouse models of ovarian and aggressive colon cancer, Tagworks Pharmaceuticals has demonstrated the potent antitumour effect of the company’s ‘click-to-release’ bioorthogonal chemistry approach. The results are published in the journal Nature Communications

Raffaella Rossin, et al., Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice, Nature Communications (2018), doi:10.1038/s41467-018-03880-y

Tagworks@Antibody Engineering & Therapeutics Europe 2018, Amsterdam

Tagworks’ CEO Marc Robillard is one of the speakers at Antibody Engineering & Therapeutics Europe 2018 in Amsterdam from 5-7 June.

Marc will present the company’s latest results on “Click chemistry-triggered drug release from a tumor-bound ADC” on Thursday 7 June. His lecture is part of a session on “Novel antibody-based therapeutics for cancer and immuno-oncology”

More information on the event: https://lifesciences.knect365.com/antibody-engineering-europe/speakers

 

Tagworks@EANM’17, Vienna

Tagworks CEO Marc Robillard will present at and co-chair the session on ‘Bioorthogonal and Click Chemistry for Molecular Imaging’ on Sunday October 21, 13:00-16:00, during the 30th Annual Conference of the European Association of Nuclear Medicine (EANM), October 21-25, 2017, Vienna, Austria.

More information on EANM’17: http://eanm17.eanm.org